OR WAIT null SECS
December 19, 2018
The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.
December 18, 2018
The company’s biosimiliar to Roche’s Avastin (bevacizumab) received a positive opinion for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
The companies will develop a digital platform for the development and lifecycle management of antibiotics.
December 14, 2018
Eli Lilly and AC Immune have signed a license and collaboration agreement focussing on the R&D of tau aggregation inhibitor small molecules for the potential treatment of neurodegenerative diseases.
December 13, 2018
A new facility in California will expand Orchard Therapeutic’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells.
December 12, 2018
The $62-billion acquisition of Shire by Takeda Pharmaceutical was approved by both sets of shareholders.
December 05, 2018
AbbVie will grant Pfizer license to launch a biosimilar to AbbVie’s Humira worldwide.
November 30, 2018
The acquisition will give Genentech full rights to Jecure’s preclinical portfolio of NLRP3 inhibitors.
November 27, 2018
The agency has approved two new chemical entities, Daurismo (glasdegib) from Pfizer, and Vitrakvi (larotrectinib) from Loxo Oncology, for treating cancers.
November 20, 2018
The vaccine producer announced an expansion to its Holly Springs, NC, manufacturing facility where it will increase production of its cell-based quadrivalent influenza vaccine.